MedDataX Logo

Randomized Clinical Trial of Standard FMT Treatments

NCT ID: NCT04729790

Last Updated: 2021-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-10

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single center, randomized, parallel assignment, double-blinded, efficacy and safety study to be conducted in subjects with recurrent C. difficile Infection (RCDI). Approximately 200 subjects will be enrolled in the study and randomized at 1:1 ratio to receive lyophilized intestinal bacteria obtained from either single or three donors (group 1 receiving healthy microbiota collected from single donor 90g stool for 2 consecutive days; group 2 receiving healthy microbiota collected from three donors 90g stool for 2 consecutive days). All subjects will be followed for approximately 180 days following FMT treatment for safety.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The endpoints of the study are to evaluate the efficacy and safety of lyophilized product by capsules obtained either from single or three donors and the prevention of subsequent bouts of CDI in 60 days post FMT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Clostridium Difficile

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a double-blinded study for the groups randomized to receive FMT products either from single or three healthy donors
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
An independent statistician will develop a randomization list using SAS. Randomization in permuted blocks will be used to achieve balance across treatment groups. The randomization scheme consists of a sequence of blocks such that each block contains a pre-specified number of treatment assignments in random order. The purpose of this is to balance the randomization scheme at the completion of each block. The target sample size is 200 evaluable subjects or as many as can be done up to that number.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with RCDI will receive FMT capsules from single donor

Capsules made with intestinal bacteria from single healthy donor

1. st treatment day, lyophilized product generated from single donor (90g of stool)
2. nd treatment day, lyophilized product generated from single donor (90g of stool)

Group Type ACTIVE_COMPARATOR

PRIM-DJ2727

Intervention Type DRUG

oral FMT capsules

Patient will receive FMT capsules from three donors

Capsules made of intestinal bacteria from three healthy donors

1. st treatment day, lyophilized product generated from three donors (90g of stool)
2. nd treatment day, lyophilized product generated from three donors (90g of stool)

Group Type EXPERIMENTAL

PRIM-DJ2727

Intervention Type DRUG

oral FMT capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRIM-DJ2727

oral FMT capsules

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female subjects 18 years of age or older.
2. Sexually active male and female subjects of childbearing potential agree to use an effective method of birth control during the study.
3. Female subjects of childbearing potential will be asked if they could be pregnant. If the subject is unsure a pregnancy test will be completed
4. Subject/LAR willing and able to provide informed consent.
5. Able to follow study procedures and complete the follow-up questionnaire for safety.
6. Subject must have an attending physician who will provide non-transplant care (Either PI of this study or referring physician).
7. Medical history of ≥ 3 bouts of CDI in outpatient or ≥ 2 bouts of CDI in inpatient with either group having ≥ 2 positive fecal tests for C. difficile toxin and at least one bout of CDI within 6 months of enrollment.
8. Received at least two courses of standard-of-care antibiotic therapy for CDI.

Exclusion Criteria

1. Unable to take capsules orally.
2. Requiring systemic non-C. difficile antibiotic therapy within 14 days prior to FMT.
3. Unwilling to stop taking non-dietary probiotics 24-96 hours prior to FMT.
4. Unable to stop taking bile acid sequestrants (e.g. cholestyramine) 24-96 hours prior to FMT.
5. Unable to stop use of drugs with CDI activity: oral vancomycin, oral or IV metronidazole, fidaxomicin, rifaximin or nitazoxanide 24-96 hours prior to FMT and after FMT.
6. Receipt of CDI monoclonal antibodies as treatment for the most recent bout of CDI.
7. Life expectancy of \< 6 months.
8. In the opinion of investigator, subject for any reason, should be excluded from the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The University of Texas Health Science Center, Houston

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Herbert DuPont, MD

Professor of Infectious Diseases

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Herbert l DuPont, MD

Role: STUDY_DIRECTOR

University of Texas Health Science Center School of Public Health

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HSC-SPH-19-0950

Identifier Type: -

Identifier Source: org_study_id